Program
bulumtatug fuvedotin
Also written as “9MW2821”, “CVL006 in combination with 9MW2821” and “9MW2821+other anticancer therapy”.
Its studies are mostly in Triple Negative Breast Neoplasms · Carcinoma, Transitional Cell · Uterine Cervical Neoplasms, led by 2 companies.
Drug pageBulumtatug fuvedotin: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mabwell (Shanghai) Bioscienceits history only | 1212 open or running | phase 3since Dec 12, 2023 | Jan 19, 2022 | Dec 31, 2026phase 2 · NCT06079112 |
| Convalife (Shanghai) | 11 open or running | phase 2since May 6, 2026 | May 6, 2026 | Apr 30, 2029phase 2 · NCT07615660 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Convalife (Shanghai) only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 11, 2024Named bulumtatug fuvedotinINNProposed as its International Nonproprietary Name in WHO's List 131
- May 6, 2026First study: phase 2 study in Advanced Solid TumorFirst studyNCT07615660 · 108 planned
Ahead
- Apr 30, 2029Primary completion: phase 2 study in Advanced Solid TumorNCT07615660
TargetBeta
“An antibody drug conjugate (ADC) composed of bulumtatug, a humanized monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4), site-specifically ”NCIt, by rule
Other programs on NECTIN4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enfortumab vedotinrule | Astellas Pharma | phase 4 | 20 |
| notiretatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 14 |
| Sutantatug Envedotinrule | CSPC Pharmaceutical Group | phase 3 | 6 |
| zelenectide pevedotinrule | bicycletx-limited | phase 2 | 5 |
| Anti-nectin-4 Antibody-drug Conjugate MK-3120rule | Merck | phase 2 | 5 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-nectin-4 Antibody-drug Conjugate IPH4502rule | innate-pharma | phase 1 | 1 |
| Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rule | rondo-therapeutics | phase 1 | 1 |
| CT-202rule | context-therapeutics-inc | phase 1 | 1 |
Studies
The one study Convalife (Shanghai) leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07615660Advanced Solid Tumor | 2 | Not yet recruiting | Apr 30, 2029 | 108 |
How it is read
Names in the registry
- “9MW2821”, 10 entries
- “bulumtatug fuvedotin”, 2 entries
- “CVL006 in combination with 9MW2821”, 2 entries
- “9MW2821+other anticancer therapy”, 1 entry
Conditions, from the studies’ own filings
- Triple Negative Breast Neoplasms, 3 studies
- Carcinoma, Transitional Cell, 2 studies
- Uterine Cervical Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.